Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.


Sehn L. H., Kamdar M., Herrera A. F., McMillan A., Flowers C., Kim W. S., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI-Expanded) identifier